Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pharmacologic therapy for urticaria

J M Negro-Alvarez1, A Carreño-Rojo, E Funes-Vera

  • 1Allergology Section, H. U. Virgen de la Arrixaca El Palmar, Murcia, Spain.

Allergologia Et Immunopathologia
|January 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fixed drug eruption due to atorvastatin.

Journal of investigational allergology & clinical immunology·2015
Same author

Chronic idiopathic urticaria treatment.

Allergologia et immunopathologia·2001
Same author

The role of rhinovirus in allergic airway inflammation.

Allergologia et immunopathologia·1998
Same author

Platelet-activating factor antagonists.

Allergologia et immunopathologia·1997
Same author

Antiallergic properties of antihistamines.

Allergologia et immunopathologia·1996
Same author

Nizatidine anaphylaxis.

The Journal of allergy and clinical immunology·1996
Same journal

Peach sublingual immunotherapy for lipid transfer protein syndrome.

Allergologia et immunopathologia·2026
Same journal

Gastrointestinal stenosis: an underrecognized complication of CARMIL2 deficiency.

Allergologia et immunopathologia·2026
Same journal

Peach sublingual immunotherapy for lipid transfer protein syndrome.

Allergologia et immunopathologia·2026
Same journal

Vitamin B12 allergy and desensitization.

Allergologia et immunopathologia·2026
Same journal

Chronic HBV infection, stemness pathways, and compromised immune surveillance in HCC development.

Allergologia et immunopathologia·2026
Same journal

Application of FeNO in the diagnostic and therapeutic algorithm of pediatric asthma: From chronic cough and wheeze to personalized management.

Allergologia et immunopathologia·2026
See all related articles

Treating chronic urticaria involves moving from sedating H1 antagonists to newer options. Corticosteroids are effective for severe cases, while research into other mediators offers future hope.

Area of Science:

  • Dermatology
  • Allergology
  • Immunology

Background:

  • Chronic urticaria (CU) poses significant challenges in clinical practice and patient management.
  • Traditional H1 antagonists, while effective, often cause sedation, leading to the use of newer, non-sedating alternatives.
  • Combination therapy with H1 and H2 antagonists shows promise for specific patient groups.

Purpose of the Study:

  • To review current and emerging treatment strategies for chronic urticaria.
  • To evaluate the efficacy and limitations of various therapeutic options.
  • To highlight the need for a deeper understanding of CU pathogenesis.

Main Methods:

  • Review of existing literature on chronic urticaria treatments.
  • Analysis of traditional H1 antagonists, newer non-sedating H1 antagonists, and combination therapies.

Related Experiment Videos

  • Evaluation of second-line treatments including corticosteroids, doxepin, dapsone, and others.
  • Discussion of potential future therapies like mast cell stabilizers and mediator inhibitors.

    • Main Results:

    • Non-sedating H1 antagonists are increasingly replacing older, sedating versions.
    • Combination H1 and H2 antagonist therapy can improve outcomes in select patients.
    • Corticosteroids are highly effective for short-term management of severe or recalcitrant chronic urticaria, including specific subtypes like pressure urticaria and urticarial vasculitis.

    Conclusions:

    • Current treatment paradigms for chronic urticaria are evolving, with a shift towards safer and more targeted therapies.
    • While corticosteroids remain crucial for severe exacerbations, their long-term use should be judicious.
    • Further research into the pathogenesis of chronic urticaria is essential for developing more rational and effective treatments.